AstraZeneca’s three-drug inhaler Breztri Aerosphere has proven efficacy for uncontrolled bronchial asthma in a pair of section 3 trials that might prolong its label past the drug’s present use in continual obstructive pulmonary illness (COPD).
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
